Skip to main content
SpringerLink
Log in

Drug–Drug Interaction – Enzyme Inhibition

  • Reference work entry
Drug Discovery and Evaluation

1 Introduction

Inhibitory drug interactionsdrug–drug interaction received considerable attention in the 1990s because some prominent drugs (e.g. terfenadine) caused life-threatening adverse effects when prescribed with other commonly used drugs (e.g. antibiotics). At about the same time, in vitro technology was developed to study drug interaction with individual human P450 enzymes by using either enzyme specific substrates or recombinant P450 isoenzymes. Along with guidance documents issued by the US FDA and the European Agency for the Evaluation of Medicinal Products, the evaluation of in vitro drug interactions have become as an integral part of the drug development process (FDA 1997, EMEA 1997).

The following discussions and assay descriptions are related to cytochrome P450 inhibition. Most drug interaction studies are related to P450 isoenzymes. Nevertheless, other enzyme systems may contribute to significant drug interactions such as transporter (e.g. Floren 1997; Abel 2001)...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 389.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, Walker DK (2001) Potential role of p-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 31(8/9):665–676

    Article  PubMed  CAS  Google Scholar 

  • Bloomer JC, Clarke SE, Chenery RJ (1995) Determination of P4501A2 activity in human liver microsomes using [3–14C-methyl]caffeine. Xenobiotica 25:917–927

    Article  PubMed  CAS  Google Scholar 

  • Bloomer JC, Woods FR, Haddock RE et al. (1992) The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Pharmacol 33:521–523

    CAS  Google Scholar 

  • Busby WF, Ackermann JM, Crespi CL (1999) Effect of Methanol, Ethanol, Dimethyl Sulfoxide, and Acetonitrile on In Vitro Activities of cDNA-Expressed Human Cytochromes P-450. Drug Metab Dispos 27:246–249

    CAS  Google Scholar 

  • Chang TK, Gonzalez FJ, Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311(2):437–442

    Article  PubMed  CAS  Google Scholar 

  • Crespi CL, Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes – state of the art and prospects for the future. Pharmacol Ther 84:121–131

    Article  PubMed  CAS  Google Scholar 

  • Dietmann K, Stork H (1976) Bilirubinemia after administration of nicotinic acid. Med Klin 71(24):1047–1050

    PubMed  CAS  Google Scholar 

  • Donato MT, Castell JV (2003) Strategies and molecular probes to investigate the role of Cytochrome P450 in drug metabolism: focus on in vitro studies. Clin. Pharmacokinet. 42(2):153–178

    Article  PubMed  CAS  Google Scholar 

  • EMEA – The European Agency for the Evaluation of Medicinal Products: Note for guidance on the investigation of drug interactions. (CPMP/EWP/560/95)http://www.emea.eu.int/pdfs/human/ewp/056095en.pdf

    Google Scholar 

  • Ekins S, Murray GI, Burke MD et al. (1995) Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. Drug Metab Dispos 23(11):1274–1279

    CAS  Google Scholar 

  • FDA- US Food and Drug Administration Centre of Drug Evaluation and Research (CDER). Guidance for industry: drug metabolism/drug interaction studies in the drug development process: Studies in vitro. http://www.fda.gov/cder/guidance/clin3.pdf

    Google Scholar 

  • Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler, BS, Lee JW, Roberts JP, Hebert MF (1997) Tacrolismus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41–49

    Article  PubMed  CAS  Google Scholar 

  • Gibbs MA, Kunze KL, Howald WN, Thummel KE (1999) Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27(5):596–599

    CAS  Google Scholar 

  • Hesse LM, Venkatakrishnan K, Court MH et al. (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28(10):1176–1183

    CAS  Google Scholar 

  • Heyn H, White RB, Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24(9):948–954

    CAS  Google Scholar 

  • Ko JW, Desta Z, Flockhart DA (1998) Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26(8):775–778

    CAS  Google Scholar 

  • Madan A, Usuki E, Burton LA, Ogilvie BW (2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD (ed) Drug-drug interactions. Marcel Dekker, Inc.

    Google Scholar 

  • McGinnity DF, Griffin SJ, Moody GC, Voice M, Hanlon S, Friedberg T, Riley RJ (1999) Rapid Characterization of the Major Drug-Metabolizing Human Hepatic Cytochrome P-450 Enzymes Expressed in Escherichia coli. Drug Metab Dispos 27:1017–1023

    CAS  Google Scholar 

  • Obach RS, Hynh P, Allen MC, Beedham C (2004) Human liver aldehyde oxidase: Inhibition by 239 drugs. J Clin Pharmacol 44:7–19

    Article  PubMed  CAS  Google Scholar 

  • Ortiz De Montellano PR (1995) The 1994 Bernard B. Brodie Award Lecture. Structure, mechanism, and inhibition of cytochrome P450. Drug Metab Dispos 23:1181–1187

    CAS  Google Scholar 

  • Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS (2001) Rational use of in vitro p-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299(2):620–628

    PubMed  CAS  Google Scholar 

  • Rae JM, Soukhova NV, Flockhart DA, Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30(5):525–530

    Article  CAS  Google Scholar 

  • Rayer CR, Esch LD, Wynn HE, Eales R (2001) Symptomatic hyperbilirubinemia with indinavir/ritonavir containing regimen. Ann Pharmacother 35(11):1391–1395

    Google Scholar 

  • Riley R, Howbrook D (1997) In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin. J Pharmacol Toxicol Methods 38(4):189–193

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues AD (1996) Measurement of human liver microsomal cytochrome P450 2D6 activity using [O-methyl-14C]dextromethorphan as substrate. Meth Enzymol 272:186–195

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues AD, Kukula MJ, Surber BW et al. (1994) Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan. Anal Biochem 219:309–320

    Article  PubMed  CAS  Google Scholar 

  • Rodrigues AD, Surber BW, Yao Y et al. (1997) [O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes. Drug Metab Dispos 25(9):1097–1100

    CAS  Google Scholar 

  • Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporter of the ATP binding cassette (ABC) family: on overview. Adv Drug Deliv Rev 55:3–29

    Article  PubMed  CAS  Google Scholar 

  • Schwab D, Fischer H, Tabatabaei A, Ploi S, Huwyler J (2003) Comparison of in vitro p-glycoprotein screening assays: Recommendation for their use in drug discovery. J Med Chem 46:1716–1725

    Article  PubMed  CAS  Google Scholar 

  • Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Therapeutics 70(2):103–114

    Article  PubMed  CAS  Google Scholar 

  • Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32(11):10–27

    Article  Google Scholar 

  • Yamazaki H, Oda Y, Funae Y et al. (1992) Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 13(6):979–985

    Article  PubMed  CAS  Google Scholar 

  • Yang CS, Patten CJ, Ishizaki H, Yoo JSH (1991) Induction, purification, and characterization of cytochrome P450IIE. Methods Enzymol 206:595–603

    Article  PubMed  CAS  Google Scholar 

  • Yuan R, Madani S, Wei XX et al. (2002) Evaluation of Cytochrome P450 Probe Substrates Commonly Used by the Pharmaceutical Industry to Study in Vitro Drug Interactions. Drug Metab Dispos 30:1311–1319

    Article  CAS  Google Scholar 

  • Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE (2001) Mechanism of indinavir-induced hyperbilirubinemia. PNAS 98(22):12671–12676

    Article  PubMed  CAS  Google Scholar 

  • www.bdbiosciences.com/discovery_labware/gentest/products/pdf/HTS_UGT1A1_AAP_7_S01T044R2.pdf

    Google Scholar 

  • www.gentest.com

    Google Scholar 

  • www.invitrogen.com

    Google Scholar 

  • www.promega.com

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Global Metabolism & Pharmacokinetics, Aventis Pharma Deutschland GmbH, Industriepark Höchst, Building G 876, 65926, Frankfurt, Germany

    Angela Dudda & Gert Ulrich Kürzel

Authors
  1. Angela Dudda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gert Ulrich Kürzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gert Ulrich Kürzel .

Editor information

Editors and Affiliations

  1. Johann-Wolfgang-Goethe-Universität, Frankfurt am Main, Germany

    H. Gerhard Vogel Prof.

  2. Altstadt 19, 64807, Dieburg, Germany

    Franz Jakob Hock Dr. (Editor) (Editor)

  3. Aventis Pharma Deutschland GmbH, Industriepark Hoechst, 65926, Frankfurt, Germany

    Jochen Maas Dr. (Co-Editor) (Co-Editor)

  4. Alte Poststraße 10, 65510, Idstein, Germany

    Dieter Mayer Prof. (Co-Editor) (Co-Editor)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg New York

About this entry

Cite this entry

Dudda, A., Kürzel, G.U. (2006). Drug–Drug Interaction – Enzyme Inhibition. In: Vogel, H.G., Hock, F.J., Maas, J., Mayer, D. (eds) Drug Discovery and Evaluation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-29804-5_28

Download citation

Publish with us

Policies and ethics

Search

Navigation